The fight over who owns the most promising technique for editing genes-cutting and pasting the stuff of life to cure disease and advance scientific knowledge-has been a rough one. A team on the West Coast, at UC Berkeley, filed patents on the method, Crispr-Cas9; a team on the East Coast, based at MIT and the Broad Institute, filed their own patents in 2014 after Berkeley's, but got them granted first.